0001104659-26-055256
SEC filingQ1 revenue held steady from DEXTENZA sales while heavy R&D investments in AXPAXLI Phase 3 trials drove operating losses deeper to -$93.3M and free cash flow to -$70.7M, advancing toward SOL-R topline data in Q1 2027.
The core dynamic remains heavy R&D spending fueling AXPAXLI's Phase 3 advancement, including the ongoing SOL-R trial with topline data expected in Q1 2027. Operating income deteriorated sharply to -$93.3 million, 46.0% worse than the -$63.9 million loss last year, as clinical trial costs outpaced revenue stability. Net income followed suit, widening 38.3% to -$88.6 million from -$64.1 million, translating to diluted EPS of -$0.40 versus -$0.38. This reflects the classic biotech trade-off: near-term losses for potential long-term value creation via first TKI-based wet AMD therapy.
G&A pressures contributed, driven by higher personnel-related costs including stock-based compensation, facility expenses, and professional fees—key levers of scaling infrastructure for commercial and clinical growth. Operating cash flow reflected this intensity, burning -$66.0 million versus -$44.7 million prior year, exacerbated by $4.7 million in capital expenditures (up from $1.9 million) for a free cash flow outflow of -$70.7 million. These dynamics signal sustained investment in pipeline momentum without disclosed cash balances, but position the company for pivotal catalysts.
Forward, management affirms R&D escalation to support product candidates, with SOL-R proceeding as planned per protocol criteria. This trajectory implies ongoing losses but hinges on Phase 3 readouts enabling NDA via 505(b)(2) pathway. DEXTENZA's stability offers downside protection, while clinical success could drive transformative upside—investors should monitor trial execution closely.